Clinical trials: Peripheral Arterial Vascular Occlusion
Coronary Artery Disease, Peripheral Arterial Disease
VasoStat vs. TR Band for Radial Hemostasis
VasoStat vs. TR Band compression for Radial Artery Hemostasis Following Transradial Catheterization Without Prior Radial Artery Access
- Trial name
- NCT04163471
- Testing
- Radial artery mechanical compression for hemostasis
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Forge Medical
Peripheral Arterial Disease
HORIZON Prospective Clinical Investigation
The objective of this clinical investigation is to demonstrate and provide long term clinical data on safety and performance of the Exist 6F NiTi stent system type FLEX \& PULL in a prospective investigation for the treatment of…
- Trial name
- NCT05234164
- Testing
- EXIST 6F NiTi Stent System FLEX, EXIST 6F NiTi Stent System PULL
- Where
- 2 sites in Italy, Poland
- Volunteers
- 69 people
- Sponsor
- Qmedics AG
Critical Limb Ischemia
ACP-01 in Patients With Critical Limb Ischemia
The primary objective of this study is to determine the efficacy and safety of intramuscular injection of ACP-01, comprised of blood-derived autologous ACPs, in subjects with critical limb ischemia who are receiving standard of…
- Trial name
- NCT02551679
- Testing
- ACP-01
- Where
- 19 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Hemostemix
Peripheral Arterial Disease, Intermittent Claudication
Utility, Safety, and Effectiveness of the Bard LifeStent 5F Vascular Stent System
The medical device being examined in this study is the Bard® LifeStent® 5F Vascular Stent System. It is intended for use in patients who suffer from peripheral artery disease (PAD).
- Trial name
- REALITY III (NCT03071146)
- Testing
- Bard® LifeStent® 5F Vascular Stent System
- Where
- 4 sites in Germany
- Volunteers
- 30 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease
Edoxaban in Peripheral Arterial Disease
This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential…
- Trial name
- ePAD (NCT01802775)
- Testing
- edoxaban, Clopidogrel, Aspirin
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 203 people
- Sponsor
- Daiichi Sankyo
Peripheral Arterial Disease
Effectiveness and Safety Study of Peripheral Balloon Dilatation Catheter in Percutaneous Transluminal Angioplasty(PTA) Procedure
The purpose of this study is to determine whether the peripheral balloon dilatation catheter (trade name: Iris) is safe an effective in PTA procedure.
- Trial name
- NCT01849601
- Testing
- percutaneous transluminal angioplasty balloon catheter
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Acotec Scientific Co., Ltd
Peripheral Arterial Disease (PAD), Moderate Risk for Cardiovascular Disease (CVD)
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
Non interventional study aimed to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index (ABI) not above 0.90 in subjects with a moderate risk of cardiovascular disease…
- Trial name
- PANDORA (NCT00689377)
- Where
- 331 sites in Belgium, France and 4 more
- Volunteers
- 9,000 people
- Sponsor
- AstraZeneca
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
SELUTION4BTK Trial
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in…
- Trial name
- NCT05055297
- Testing
- SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA)
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 376 people
- Sponsor
- M.A. Med Alliance S.A.
Arterial Occlusive Diseases
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
- Trial name
- NCT00338585
- Testing
- alfimeprase
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- ARCA Biopharma, Inc.
Arterial Occlusive Diseases
The Study to Treat Superficial Femoral Artery Occlusions.
The main objective of this study is to assess the performance of the Cordis SMART™ nitinol self-expandable stent for the treatment of superficial femoral artery (SFA) occlusions in comparison with balloon angioplasty only as…
- Trial name
- SUPER UK (NCT00232843)
- Testing
- stent, angioplasty
- Where
- 2 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.
Peripheral Artery Disease
A Prospective Study of the Performance of the Bard® LifeStent® Vascular Stent Systems (REALITY)
The purpose of this study is to assess the deliverability, clinical utility and effectiveness of the 5 mm diameter size offering of the LifeStent® Vascular Stent
- Trial name
- REALITY (NCT01920308)
- Testing
- 5 mm Bard LifeStent Vascular Stent
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- C. R. Bard
Peripheral Vascular Diseases
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
The particular aim of this study is the comparison of the diagnostic results of MRA images upon application of Vasovist (gadofosveset), a contrast agent not yet available on the market, with the MRA images upon application of a…
- Trial name
- NCT00296855
- Testing
- Vasovist (BAY86-5283, MS-325)
- Where
- 26 sites in Argentina, Austria and 4 more
- Volunteers
- 261 people
- Sponsor
- Bayer
Intermittent Claudication, Atherosclerotic Disease
Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study
The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral…
- Conditions
- Intermittent Claudication, Atherosclerotic Disease, Arterial Occlusive Disease
- Trial name
- RESILIENT (NCT00673985)
- Testing
- Percutaneous Transluminal Angioplasty, LifeStent NT™ Self-Expanding Peripheral Stent
- Volunteers
- 246 people
- Sponsor
- C. R. Bard
Peripheral Artery Disease
A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System
The purpose of this study is to assess the deliverability, clinical utility, safety and effectiveness of the 250 mm length size offering of the LifeStent® Vascular Stent.
- Trial name
- REALITY2 (NCT02262949)
- Testing
- LifeStent Vascular Stent
- Where
- 4 sites in Germany
- Volunteers
- 31 people
- Sponsor
- C. R. Bard
Peripheral Artery Disease, Atherosclerosis
SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease
This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial…
- Conditions
- Peripheral Artery Disease, Atherosclerosis, Arterial Disease of Legs
- Trial name
- FUTURE-BTK (NCT04511247)
- Testing
- MagicTouch PTA Sirolimus drug coated balloon, POBA balloon
- Where
- 20 sites in Singapore, Taiwan and 1 more
- Volunteers
- 219 people
- Sponsor
- Concept Medical Inc.
Peripheral Arterial Disease
Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease
The goal of this clinical trial is to study the safety and tolerability of Etrinabdione in adult patients with peripheral arterial disease. It will also learn about the preliminary efficacy of Etrinabdione.
- Trial name
- CLAUDIA (NCT06774040)
- Testing
- Etribnabdione 25 mg BID, Etribnabdione 50 mg BID
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- VivaCell Biotechnology España